Advice for Com-COV/Com-COV2 participants about receiving a booster dose (‘3rd dose’) in the Autumn 2021 NHS campaign.
All participants in the Com-COV and Com-COV2 studies will be eligible to receive a 3rd dose of a COVID vaccine as part of the NHS autumn booster dose campaign.
Details of this programme for clinical trial participants are described at:
https://bepartofresearch.nihr.ac.uk/Vaccine-studies/Latest-Vaccine-News
The specific advice for participants and actions required differs according to the vaccine study and, for Com-COV2 participants, the vaccines received. All Com-COV and Com-COV2 participants should now have been unblinded and informed of which vaccine(s) they have received in the trials. Depending on the trial and the vaccines received in the trial, there may be some planning required before taking up a third COVID-19 vaccine dose, being offered via the national roll-out.
For all Com-COV participants AND Com-COV2 participants receiving:
• Oxford AstraZeneca followed by Oxford AstraZeneca
• Pfizer followed by Pfizer
• Pfizer followed by Moderna
All participants in the above groups will be able to receive a booster dose of the Pfizer vaccine through any NHS Immunisation site once they have received an invitation from the NHS to do so. Participants are advised to carry the ‘Letter to trial participants of approved vaccines re boosters’ that was sent by the trial site team. Further information on the website link above. No additional planning is required.
For Com-COV2 participants receiving:
• Oxford AstraZeneca followed by Moderna
Participants in the above group will also be able to receive a booster dose of the Pfizer vaccine through any NHS Immunisation site once they have received an invitation from the NHS to do so.
However, the choice of booster dose may have implications for travel certification. Therefore, we would encourage these participants to discuss the choice of the third dose with their study site, prior to booking a vaccination appointment.
For Com-COV2 participants receiving:
• Oxford AstraZeneca followed by Novavax
• Pfizer followed by Novavax
Participants in the above groups are eligible for a booster dose, however, as the Novavax vaccine is yet to be approved as a licensed COVID-19 vaccine, there is a requirement for a discussion with the site, and a signed document to enable invitation to and administration of a booster dose at selected immunisation sites. The details of this process are being finalised and your site team will contact you as soon as there is more information.
Thank you for your participation.
